2Q2026 Earnings Report

Aug 12, 2026

Investor Relations
ir@eyecenter.com.tw

Universal Vision Biotechnology

Universal Vision Biotechnology

Ticker	Established	Listed
3218TT	1994	2004
Capital	**Founders**	**Group Employees**
847M TWD	Dr. Pi-Jung Lin Dr. Shu-Fang Ou	600+ 1300+ (clinic included)

Taiwan's No.1 Eye Care Brand
One Stop Ophthalmology + Optometry Integration
The Vision Care Consolidator & Total Solution Provider

Three Target Generations & Core Businesses

	Teens 9-18 years	Adults 20-50 years	Seniors 55+ years
Ophthalmology	 Myopia Management	 Refractive Correction	 Cataract Treatment
Optometry	Corrective Lenses	Myopic Lenses Contacts & RGP	Progressive Lenses

Service Regions & Business Models

UVB

Taiwan
Since 1994

Ophthalmology

Franchise Model (B2B)
- Brand Licensing
- Clinical Consulting
- Medical Equipment & Supplies Procurement
- Store Expansion Planning
- Sales, Marketing & HR Supports

大學眼科 Universal Eye Center

Optometry

Self Operation (B2C)

大學眼鏡 Universal Optical Center

Eastern China
Since 2012

Ophthalmology

Hospital Partnership (B2B)
- Clinical Consulting
- Medical Equipment & Supplies Procurement
- Co-brand Marketing

Ophthalmology

Optometry

Self Operation (B2C)

大学眼科 Universal Eye Center

As of Jul 2026

33 Affiliated Clinics	36 Optical Stores	5 Partnered Hospitals	4 Clinics/Hospitals

UVB's Core Competencies in the Industry

UVB Management (B2B)

Leading Technology & Procurement Capability

- Cutting edge medical technology & equipment
- Strong procurement and supply chain management

Professional Administrative Consulting & Support

- Experiences of sales, marketing, store expansion, HR, etc.
- Maximize efficiency and performance for stores

Proven Successful Franchise Business Model

- Leverage corporate capital to invest in high end medical equipment
- Duplicable business success attracts more doctors to join the brand

Retail Service (B2C)

Strong Medical & Optical Expertise

- Experts of practitioners, surgeons and opticians in the network
- Comprehensive clinical application services and training platform

Excellent Medical & Service Quality

- Assisted clinics to acquire JCI Accreditation 5 times since 2010
- One stop compound shop for professional vision care solutions

No.1 Vision Care Brand

大學眼視光體系

- The dominator enjoying 50% of the refractive market share
- Reputable name and high customer satisfaction

High Myopia Prevalence Relating to Increasing Demands for Vision Improvement

- Long exposure to electronic devices has been causing early development of various eye diseases.
- In both Taiwan & China, over 80% of the teenagers suffers from myopia when they turn 18.
- Increasing demands under still low surgery penetration with the rise of technology and acceptance.

Myopia Prevalence in TW & CN, 2018



Source: *Statistic Bureau, R.O.C. Taiwan, Morgan Stanley Research National Health Commission of the People's Republic of China*

Low Penetration of Refractive Surgery

	TW	CN
Population Eligible for Refractive Surgery	12M	700M
# of Refractive Surgery in 2022	38,000	2.4M
Penetration (annual)	0.32%	0.34%

Source: *The Ophthalmologist, Internal Data*

Myopia Control Solutions for Teens

One-Stop Myopia Control Solutions



Orthokeratology

Daily Disposable Soft Contact Lens

Defocus Incorporated Multiple Segments (DIMS) Lens

Atropine

Professional Service by UVB 大學

Strong medical team
Prescriptions issued by doctors

Comprehensive outpatient consultation
Attentive follow-up management

Cutting-edge global technology
AI-driven precise fitting

Nationwide service locations
24-hour customer care hotline

Extensive optical experiences
Over 59,000 successful cases

Core Business & Driver for UVB's optometry in Taiwan

Refractive Surgery – Introducing Innovative Technology

Pioneering Leadership through Revolutionary Equipment and All-Inclusive Surgical Solutions

1997	Dec 2019	Dec 2022	Oct 2024	January 2026
LASIK introduced	SMILE introduced	SMILE PRO introduced	SMILE PRO 2.0 introduced	**SMILE PRO MAX 3.0 introduced**

SMILE = Small Incision Lenticule Extraction, proprietary technology of Zeiss

SMILE

8 (10-2) Machines

SMILE PRO

12+1 Machines

SMILE pro 3.0 Max

Next-Gen Femtosecond Laser Vision Correction

AI-Powered · **Precise** · **Rapid** · **Minimally Invasive**

SMILE Series Dominates Taiwan's Refractive Surgery Market

Revolutionary Technology Redefining Vision Correction

STAARSURGICAL™

EVO ICL = Implantable **Collamer®** Lens
(EVO = evolution)

- High biocompatibility with collagen protein
- Soft, flexible, and elastic
- UV protection

30+ Years on the market

4+ Million ICL lenses distributed worldwide

FDA approved in
EU, USA, Japan, Taiwan

Ideal for Moderate to High Myopia

- Myopia: -3.00D to -20.00D
- Astigmatism: +1.00D to +4.00D
- Age: 21–60 years

- Reversible and removable
- Rapid surgery and recovery
- 0.3cm micro-incision
- No cause of dry eyes




讓我們看看這個快速而簡單的ICL植入過程

EVO ICL vs. ARTIFLEX

Posterior Chamber

Anterior Chamber

	EVO ICL (Posterior Chamber)	ARTIFLEX (Anterior Chamber)
Indications	Myopia: -3.00D to -20.00D Astigmatism: +1.00D to +4.00D	Myopia: -8.00D to -14.50D Astigmatism: +1.00D to +5.00D
Placement	Behind the iris & in front of the natural crystalline lens (difficult to see)	In front of the iris (visible)
Fixation	Natural anatomical fit: preserves corneal structure & biomechanics	Clips onto the surface of the iris: alters corneal architecture and biomechanics
Iridectomy	Not Required	May be Required
Clinical Cases	4 Million*	Fewer (no official data)

Source: STAAR Surgical, 2024

Taiwan to Become a “Super-Aged Society“ by 2025



Potential Targets for

Aged 55+
7.83M, 33%
Cataract/Presbyopia Treatment

Aged 40-54
5.66M, 24%
Refractive/Presbyopia Treatment

Aged 20-39
6.10M, 26%
Refractive/Myopia Treatment

Based on population in 2023

Promising Potential for Presbyopia Correction Demand

Laser Vision Correction for Presbyopia

SMILE Series

- Minimally Invasive, 0.2 cm micro-incision
- Fast recovery, lower risk of dry eyes
- Ideal for patients needing quick visual recovery and with mild presbyopia symptoms

PRESBYOND® Laser Blended Vision (LBV)

- Customized treatment parameters
- Enhance stereoacuity, intermediate and overall vision quality
- Ideal for patients with significant presbyopia symptoms

PRESBYOND® Laser Blended Vision Technology



- Customized treatment profiles
- Optimize stereoacuity, eliminate multiple images
- All distances – near, intermediate to far
- Ideal for Reading & Digital Device Users

PRESBYOND® LBV 4 Machines introduced since Dec 2022

Cataract Treatment - Advanced FLACS & Premium IOL

Focus on World-Class Technology and Top-Tier Offerings of Cataract Treatment

Ziemer - FEMTO LDV Z8

LenSx

- **FLACS = Famtosecond Laser Assisted Cataract Surgery**

32+1 Machines

High Precision & Safety
AI Customization
Fast Post-Surgery Recovery
Excellent Visual Quality

- **IOL = Intraocular Lens**

Full range of functional lenses tailored to individual needs
Monofocal, bifocal, multifocal, toric (astigmatism), myopia and presbyopia correcting

Stable Growth of High-End Elective Services in Taiwan

2026 Store Expansion Plans

TAIWAN

Franchise Business :
Brand Licensing &
Clinical consulting services

33

- **Existing Centers**
  - Space Enlargement
  - Equipment Upgrades → **6 Renovations**
  - Capacity Increase
- **New Centers**
  - Mid & South Taiwan
  - Metropolitan Areas
  - Network Extension

  + 2 Centers (completed)

CHINA



Self-Operation : 4
Hospital Partnership : 5

9

- **Existing Centers**
  - Space Expansion
  - Equipment Upgrades
  - Capacity & Service Increase
- **New Centers**
  - Hospital Partnership
  - Clinic Acquisition

  + 1 Centers (Q12027)

2025-2026YTD Taiwan Store Expansions

Launched in Mar 2025

ARTS CENTER, TAOYUAN

Launched in Jul 2025

ZHUBEI, HSINCHU

Launched in Sep 2025

CHONGDE, TAICHUNG



HENAN, KEELUNG

Soft Opening in Feb 2026

TAOYUAN

Expanded & Relocated in Aug 2026

DOULIU, YUNLIN

Luanched in Mar 2026

PENGHU Universal Optical

Upgraded in May 2026

Brand New Yunlin Douliu Eye Center

Douliu Universal Eye Center – Launched in March 2026

- The first partnered clinic in Yulin, located within the Douliu Taiping Street commercial district.
- Approximately 1,160 m^2 across 4 floors, including two operating rooms.
- Equipped with SMILE refractive surgery and femtosecond laser cataract systems, together with a brand-new optical retail center.

Brand New Keelung Henan Eye Center

Henan Universal Eye Center – Soft Opening in February 2026

- The first partnered clinic in Keelung, located in the city center with a medical clinic cluster; close to the Keelung Port commercial district and night market area.
- Approximately 330 m^2 of space on one floor, including two operating rooms.
- SMILE and femtosecond cataract platforms, with a new optical retail center to be introduced.

Expansion & Relocation - Taoyuan Eye Center

Taoyuan Universal Eye Center – Relocated to New Premises in August 2026

- Prime location near Taoyuan Railway Station, with 2x the floor space and number of floors; less than a 5-minute walk from the original site.
- Approx. 1,157 m^2 in a standalone four-story building, three operating rooms, and premium interior design.

2026 China Expansion – Jiangsu Universal Eye Hospital

- **Healthcare liberalization pilot city**
- **Approval for foreign-invested hospitals**
- **Introduction of international-standard healthcare**

Groundbreaking ceremony for Universal Eye Hospital. Jan 12, 2026

Government Support

Transport Hub

- **Suzhou North High-Speed Rail Station – integrated transport and commercial complex**
- **Rapid connectivity across the Yangtze River Delta**
- **Emerging Xiangcheng District**

Policy Incentives

- **Rent exemptions**
- **~3,200m² planned facility**
- **Lower development and operating costs**

Strategic Positioning

- **First private foreign-invested tertiary ophthalmology specialty hospital in the country**
- **Strong government partnerships supporting market expansion**

- **Expansion completion targeted in 2027**
- **Hangzhou and Ningbo reachable within 50 minutes**

2Q2026 Consolidated Statements of Income

Items in Thousand TWD	2Q2026	%	1Q2026	%	QoQ	2Q2025	%	YoY
Operating Revenue	**1,126,489**	**100**	1,089,806	100	**3.4%**	1,022,944	100	**10.1%**
Operating Costs	**476,298**	**42.3**	464,479	42.6		418,519	40.9	
Gross Profit	**650,191**	**57.7**	625,327	57.4	**+0.3ppt**	604,425	59.1	**-1.4ppt**
Operating Expenses	**302,278**	**26.8**	291,473	26.7	**+0.1ppt**	270,325	26.4	**+0.4ppt**
Operating Profit	**347,913**	**30.9**	333,854	30.6	**4.2%**	334,100	32.7	**4.1%**
Non-operating Income & Expenses	**(52,957)**	**(4.7)**	21,044	1.9		(206,379)	(20.2)	
Profit Before Income Tax	**294,956**	**26.2**	354,898	32.6		127,721	12.5	
Income Tax	**69,278**	**6.1**	66,969	6.1		85,139	8.3	
Net Profit	**225,678**	**20.0**	287,929	26.4		42,582	4.2	
Net Profit Attributable to Owners of the Parent	**226,460**	**20.1**	280,773	25.8	**-19.3%**	42,508	4.2	**432.7%**
Non-Controlling Interest	**(782)**	**(0.1)**	7,156	0.7		74	0.0	
EPS (NT$)	**2.67**		3.31			0.50		

1H2026 Consolidated Statements of Income

Items in Thousand TWD	1H2026	%	1H2025	%	YoY
Operating Revenue	**2,216,295**	**100**	2,146,164	100	**3.3%**
Operating Costs	**940,777**	**42.4**	875,131	40.8	
Gross Profit	**1,275,518**	**57.6**	1,271,033	59.2	-1.6ppt
Operating Expenses	**593,751**	**26.8**	544,273	25.4	+1.4ppt
Operating Profit	**681,767**	**30.8**	726,760	33.8	-6.2%
Non-operating Income & Expenses	**(31,913)**	**(1.4)**	(148,264)	(6.9)	
Profit Before Income Tax	**649,854**	**29.3**	578,496	26.9	
Income Tax	**136,247**	**6.1**	165,745	7.7	
Net Profit	**513,607**	**23.2**	412,751	19.2	
Net Profit Attributable to Owners of the Parent	**507,233**	**22.9**	405,156	18.9	**25.2%**
Non-Controlling Interest	**6,374**	**0.3**	7,595	0.3	
EPS (NT$)	**5.99**		4.78		

Sales Breakdown by Business



Optometry
Ophthalmology

In million TWD



Ophthalmology	2025	1H2026
Technical Service	**50%**	**47%**
Medical Supplies	**15%**	**19%**
Consulting	**4%**	**4%**
Store Rent	**5%**	**5%**

Universal Vision Biotechnology

Sales Breakdown by Region







See Clear • See Comfort • See the Future

Continuous Financial Progress





ROE & ROA

	YEAR	2020	2021	2022	2023	2024	2025	2026
Consolidated	**ROE**	25.9%	28.0%	33.7%	34.5%	29.6%	26.7%	**25.5%**
	ROA	17.0%	18.0%	21.3%	22.4%	19.6%	18.1%	**16.8%**
Parent (Standalone)	**ROE**	27.6%	29.0%	35.1%	35.8%	31.3%	27.3%	**25.7%**
	ROA	18.9%	19.4%	22.9%	23.8%	21.3%	19.0%	**17.5%**

- ROE figures are annualized based on average equity attributable to shareholders of the parent company.
- ROA figures are annualized based on average total asset.

Dividend Payout Ratio

YEAR	2021	%	2022	%	2023	%	2024	%	2025	%
EPS	7.82	100%	10.64	100%	12.34	100%	12.57	100%	**12.31**	**100%**
Dividend	5.5	70%	6.6	62%	7	57%	7.5	60%	**7.75**	**63%**
- Cash **- Stock**	5 0.5	64% 6%	6 0.6	56% 6%	7 0	57% 0%	7.5 0	60% 0%	**7.75** **0**	**63%** **0%**
Capital	761M		799M		847M		847M		**847M**	

Steady Growth Momentum



2026 Revenue	2025 Revenue	YoY%
2,622	2,486	5.5%

Thank You

Investor Relations
ir@eyecenter.com.tw